Most Popular
-
1
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
2
Jung's paternity reveal exposes where Korea stands on extramarital babies
-
3
Seoul city opens emergency care centers
-
4
Opposition chief acquitted of instigating perjury
-
5
Samsung entangled in legal risks amid calls for drastic reform
-
6
[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
-
7
[Exclusive] Hyundai Mobis eyes closer ties with BYD
![[Exclusive] Hyundai Mobis eyes closer ties with BYD](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050044_0.jpg&u=)
-
8
Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
-
9
[Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance
![[Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050072_0.jpg&u=)
-
10
Why S. Korean refiners are reluctant to import US oil despite Trump’s energy push
![[Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/26/20241126050017_0.jpg&u=20241126161719)
![[Exclusive] Hyundai Mobis eyes closer ties with BYD](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050044_0.jpg&u=)
![[Herald Review] 'Gangnam B-Side' combines social realism with masterful suspense, performance](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050072_0.jpg&u=)
Celltrion acquires a unit in Takeda's APAC business
By Lim Jeong-yeoPublished : June 11, 2020 - 18:30
Celltrion announced on Thursday that it acquired the Primary Care unit in Japanese multinational pharmaceutical firm Takeda's Asia Pacific business.
The deal, worth 332.4 billion won ($278 million), will give Celltrion the rights to 18 of Takeda’s patented drugs in the APAC region that covers nine countries including Korea.
Takeda has 12 prescription drugs and six over-the-counter drug brands distributed in the Asia Pacific region.
Celltrion said that this global merger-acquisition deal, the first of its kind for the company, will give it more ammunition in the chronic illness treatments front such as for diabetes and hypertension.
Takeda had been financially pinched after making a mega-acquirement of rare disease treatment developer Shire, after which it put out business units for sale.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
The deal, worth 332.4 billion won ($278 million), will give Celltrion the rights to 18 of Takeda’s patented drugs in the APAC region that covers nine countries including Korea.
Takeda has 12 prescription drugs and six over-the-counter drug brands distributed in the Asia Pacific region.
Celltrion said that this global merger-acquisition deal, the first of its kind for the company, will give it more ammunition in the chronic illness treatments front such as for diabetes and hypertension.
Takeda had been financially pinched after making a mega-acquirement of rare disease treatment developer Shire, after which it put out business units for sale.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
